Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
Improved anti-CD154 antibodies are provided herein which have ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation and allergic disorders is disclosed herein.
1. A method of immune therapy which comprises the administration of a therapeutically effective amount of a human or humanized anti-CD154 antibody that antagonizes CD154/CD40 signaling to a subject in need thereof, wherein said human or humanized anti-CD154 antibody is of the IgG1 isotype, and comprises an E269R mutation and a K322A mutation, wherein said mutations respectively eliminate FcR binding and C1Q binding.
2. The method of claim 1 , wherein the treated subject has an allergic, autoimmune, or inflammatory condition.
3. The method of claim 1 which suppresses humoral immunity.
4. The method of claim 1 which suppresses T cell immunity.
5. The method of claim 2 , wherein the autoimmune condition is a disease selected from the group consisting of rheumatoid arthritis, Myasthenia gravis, systemic lupus erythematosus, Graves' disease, idiopathic thrombocytopenia purpura, hemolytic anemia, diabetes mellitus, psoriasis, inflammatory bowel disease, Addison's disease, Crohn's disease, uveitis, multiple sclerosis, lupus, and drug-induced autoimmune diseases.
6. The method of claim 2 wherein the autoimmune condition is a T cell-mediated autoimmune condition.
7. The method of claim 1 which treats or prevents GVHD.
8. The method of claim 1 wherein the treated subject is a transplant recipient.
9. The method of claim 8 , wherein the transplant recipient is a bone marrow transplant recipient.
10. The method of claim 1 , wherein the treated subject has cancer.
11. The method of claim 2 , wherein the treated allergic condition is asthma.
12. The method of claim 1 , wherein said anti-CD154 antibody comprises the V L complementarity determining regions (CDRs) of SEQ ID NO: 17, 18, and 19 and the V H CDRs of SEQ ID NO: 24, 25 and 26.
13. The method of claim 1 , wherein the V L polypeptide of said antibody has the amino acid sequence of SEQ ID NO: 13, 14, 15 or 16 and a V H polypeptide have the amino acid sequence of SEQ ID NO: 20, 21, 22 or 23.